Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

Anti-VEGF (vascular endothelial growth factor) therapy with the monoclonal antibody bevacizumab can cause gastrointestinal (GI) perforations. In recent years it became apparent that GI perforations also occur during treatment with antiangiogenic tyrosine kinase inhibitors (TKIs). It is of clinical i...

Descripción completa

Detalles Bibliográficos
Autores principales: Walraven, Maudy, Witteveen, Petronella O., Lolkema, Martijn P. J., van Hillegersberg, R., Voest, Emile E., Verheul, H. M. W.
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2010
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102838/
https://www.ncbi.nlm.nih.gov/pubmed/21188500
http://dx.doi.org/10.1007/s10456-010-9197-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102838/
https://www.ncbi.nlm.nih.gov/pubmed/21188500
http://dx.doi.org/10.1007/s10456-010-9197-6

Ejemplares similares